Tumor immunotherapy represents a groundbreaking cancer treatment strategy, focusing on immune checkpoints like programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), that suppress T cell activation and proliferation, enabling tumors to evade immune detection (4). This evidence concerns the gene CD274 and neoplasm.